Large-Area Plasma Panel Detectors for Particle Beam Radiation Therapy

用于粒子束放射治疗的大面积等离子体面板探测器

• 批准号: 9137921
• 负责人: Peter S Friedman
• 金额: $ 58.14万
• 依托单位: INTEGRATED SENSORS, LLC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-07 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9137921
• 关键词: Applications Grants; Area; Cells; Clinical; Data; Data Analyses; Detection; Development; Device Designs; Devices; Diagnostic; Diagnostic radiologic examination; Educational workshop; Electrodes; Electronics; Funding; Future; Gases; Glass; Goals; Image; Ions; Joints; Metals; Methods; Modeling; Monitor; Monte Carlo Method; Noble Gases; Performance; Phase; Plasma; Property; Protons; Radiation; Radiation therapy; Reaction Time; Refractory; Reporting; Request for Applications; Resolution; Safety; Scanning; Series; Silicon; Small Business Innovation Research Grant; System; Technology; Testing; Thick; Treatment Efficacy; Variant; advanced simulation; base; cancer therapy; clinical application; commercialization; cost; design; detector; digital; imaging system; improved; meetings; millimeter; novel; particle; particle beam; particle therapy; programs; proton beam; prototype; public health relevance; research and development; response; scale up; sensor; simulation; success; technology development; treatment program

 DESCRIPTION (provided by applicant): A joint DOE-NCI workshop on ion beam therapy (January 2013, Bethesda, MD) identified an ambitious set of technology developments needed to support a world-class treatment program for ion beam therapy. One important requirement is the ability to provide detectors that afford single-particle registration at high data rates with hgh degree of uniformity and minimal interference with the particle beam. This would allow performing proton or ion CT prior to treatment and 2D proton/ion radiography during treatment for integrated range verification, along with beam diagnostics that have minimal interference with the primary beam. Current silicon detectors employed in first developments of proton imaging systems have major limitations in terms of maximum available detector size. Limitations also exist for currently used beam monitoring detectors that are not suitable for very fast response times at high beam intensities required for future clinical applications of particle beam scanning. We propose to develop a novel detector, the plasma panel sensor (PPS), that has the potential to remove all the barriers of existing detectors and should therefore allow particle beam radiation therapy to realize its fullest potential to be used in future clinical particle beam therapy centers. Fundamentally the proposed detectors should be inherently uniform and of low mass with fast response time. During Phase I we were successful manufacturing ultrathin-PPS glass substrates (i.e., 0.30, 0.20 and 0.026 mm thickness) with electrode pitches of 2.54 mm and 0.35 mm, corresponding to theoretical spatial resolutions of ~ 0.73 mm and 0.10 mm, respectively, as demonstrated with Geant4 Monte Carlo simulations. Sub-millimeter image resolution thus seems eminently achievable, and when combined with potentially high particle detection efficiencies could make these detectors the technology of choice for both imaging and beam monitoring sensors in the particle therapy treatment room. In this 36-month Phase II SBIR we propose to: (1) fabricate and test on a clinical beam line a series of progressively larger and higher resolution, ultrathin-PPS devices with 2D readout; (2) develop Geant4 Monte Carlo simulation models of the detector prototypes to assist in data analysis, device design refinement, and performance optimization; and (3) demonstrate that the ultrathin-PPS devices will meet the clinical requirements as summarized in our Phase-I Final Report. Meeting the target objectives of this SBIR Phase II will enable Integrated Sensors to generate the Phase III funds to produce a universal detector system that will improve both treatment efficacy and the safety of particle beam therapy with protons and ions.

 描述（由适用提供）：关于离子束治疗的联合DOE-NCI研讨会（2013年1月，马里兰州贝塞斯达）确定了支持世界一流的ION BEAM治疗计划所需的雄心勃勃的技术发展集。一个重要的要求是能够提供以高数据速率提供单粒子注册的探测器，其均匀性程度且对颗粒束的干扰最小。这将允许在处理过程中进行质子或离子CT以及在综合范围验证的处理过程中以及2D质子/离子放射线照相以及对主要梁干扰最小干扰的束诊断。在最大可用检测器大小方面，质子成像系统初次开发的当前硅检测器具有重大局限性。当前使用的光束监测探测器也存在局限性，这些检测器不适合在粒子梁扫描所需的临床应用所需的远光强度下非常快速的响应时间。我们建议开发一种新型检测器，即等离子体面板传感器（PPS），该传感器有可能消除现有检测器的所有障碍，因此应允许颗粒束放射疗法实现其在将来的临床粒子束中使用的最大潜力 治疗中心。从根本上讲，所提出的检测器应固有地均匀，质量低，并具有快速响应时间。在第一阶段，我们成功地制造了超薄的PPP玻璃基质（即0.30、0.20和0.026 mm厚度），电极螺距为2.54 mm和0.35 mm，分别与GEEANT4 MONTE CARPULESS所示，分别对应于〜0.73 mm和0.10 mm的理论空间分辨率，分别为〜0.73 mm和0.10 mm。因此，亚毫米图的分辨率似乎取得了出色的成功，并且与潜在的高颗粒检测能力相结合时，可以使这些检测器成为粒子治疗室中成像和光束监测传感器的首选技术。在这个36个月的II阶段SBIR中，我们建议：（1）在临床束系上制造和测试一系列逐渐更大和更高的分辨率，具有2D读数的Ultrathin-PPS设备； （2）开发探测器原型的Geant4 Monte Carlo模拟模型，以帮助数据分析，设备设计改进和性能优化； （3）证明超大型PPS设备将满足我们最终报告中总结的临床要求。实现该SBIR II期的目标目标将使集成的传感器能​​够生成第三阶段资金，以产生通用检测器系统，以提高治疗效率和使用质子和离子的粒子束治疗的安全性。